6.
Palanikumar L, Kalmouni M, Houhou T, Abdullah O, Ali L, Pasricha R
. pH-Responsive Upconversion Mesoporous Silica Nanospheres for Combined Multimodal Diagnostic Imaging and Targeted Photodynamic and Photothermal Cancer Therapy. ACS Nano. 2023; 17(19):18979-18999.
PMC: 10569106.
DOI: 10.1021/acsnano.3c04564.
View
7.
Amable L
. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016; 106:27-36.
DOI: 10.1016/j.phrs.2016.01.001.
View
8.
Karbownik A, Szalek E, Urjasz H, Gleboka A, Mierzwa E, Grzeskowiak E
. The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Contemp Oncol (Pozn). 2013; 16(5):435-9.
PMC: 3687456.
DOI: 10.5114/wo.2012.31775.
View
9.
Greene R, Chatterji D, Hiranaka P, Gallelli J
. Stability of cisplatin in aqueous solution. Am J Hosp Pharm. 1979; 36(1):38-43.
View
10.
Astolfi L, Ghiselli S, Guaran V, Chicca M, Simoni E, Olivetto E
. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation. Oncol Rep. 2013; 29(4):1285-92.
PMC: 3621656.
DOI: 10.3892/or.2013.2279.
View
11.
Torres M, Khan S, Duplanty M, Lozano H, Morris T, Nguyen T
. Raman and Infrared Studies of Platinum-Based Drugs: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, and Heptaplatin. J Phys Chem A. 2018; 122(34):6934-6952.
DOI: 10.1021/acs.jpca.8b04023.
View
12.
Palanikumar L, Al-Hosani S, Kalmouni M, Nguyen V, Ali L, Pasricha R
. pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. Commun Biol. 2020; 3(1):95.
PMC: 7054360.
DOI: 10.1038/s42003-020-0817-4.
View
13.
Koopman G, Reutelingsperger C, Kuijten G, Keehnen R, Pals S, van Oers M
. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994; 84(5):1415-20.
View
14.
Raghavan R, Cheriyamundath S, Madassery J
. Dimethyl sulfoxide inactivates the anticancer effect of cisplatin against human myelogenous leukemia cell lines in in vitro assays. Indian J Pharmacol. 2015; 47(3):322-4.
PMC: 4450560.
DOI: 10.4103/0253-7613.157132.
View
15.
Abe T, Matsumoto D, Nakayama T, Shimazaki Y, Sagara A, Kanehira D
. Effect of different shielding conditions on the stability of Cisplatin. J Pharm Health Care Sci. 2020; 6:3.
PMC: 7066770.
DOI: 10.1186/s40780-020-00163-x.
View
16.
Ferlay J, Colombet M, Soerjomataram I, Parkin D, Pineros M, Znaor A
. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; .
DOI: 10.1002/ijc.33588.
View
17.
Petsko G
. Cancer chemotherapy. Heavy metal revival. Nature. 1995; 377(6550):580-1.
DOI: 10.1038/377580a0.
View
18.
Sharma S, Al Hosani S, Kalmouni M, Ramdas Nair A, Palanikumar L, Pasricha R
. Supercritical CO Processing Generates Aqueous Cisplatin Solutions with Enhanced Cancer Specificity. ACS Omega. 2020; 5(9):4558-4567.
PMC: 7066560.
DOI: 10.1021/acsomega.9b03917.
View
19.
Munaweera I, Shi Y, Koneru B, Patel A, Dang M, Di Pasqua A
. Nitric oxide- and cisplatin-releasing silica nanoparticles for use against non-small cell lung cancer. J Inorg Biochem. 2015; 153:23-31.
DOI: 10.1016/j.jinorgbio.2015.09.002.
View
20.
Parhizkar M, Reardon P, Harker A, Browning R, Stride E, Pedley R
. Enhanced efficacy in drug-resistant cancer cells through synergistic nanoparticle mediated delivery of cisplatin and decitabine. Nanoscale Adv. 2022; 2(3):1177-1186.
PMC: 9419023.
DOI: 10.1039/c9na00684b.
View